<DOC>
	<DOCNO>NCT01493505</DOCNO>
	<brief_summary>The purpose study determine whether AMG 386 AMG 386 Placebo combination Paclitaxel Carboplatin effective treatment ovarian cancer .</brief_summary>
	<brief_title>TRINOVA-3 : A Study AMG 386 AMG 386 Placebo Combination With Paclitaxel Carboplatin Treat Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Female subject 18 year age old FIGO Stages IIIIV epithelial ovarian , primary peritoneal fallopian tube cancer indication firstline treatment paclitaxel carboplatin x 6 cycle ( Subjects pseudomyxoma , mesothelioma , adenocarcinoma unknown primary tumour , carcinosarcoma , sarcoma , mucinous neuroendocrine histology exclude Subjects FIGO Stage IIIA IIIB disease must undergo PDS ovarian , primary peritoneal fallopian tube cancer within 12 week prior randomization Subjects FIGO Stage IIIC IV disease must either : Undergo PDS epithelial ovarian , primary peritoneal fallopian tube cancer within 12 week prior randomization Plan IDS follow 3 cycle paclitaxel carboplatin plus AMG 386 AMG 386 placebo biopsy proven epithelial ovarian , primary peritoneal fallopian tube cancer ECOG performance status 0 1 Adequate bone marrow , renal hepatic function Prior use anticancer therapy experimental therapy epithelial ovarian , primary peritoneal fallopian tube cancer Previous abdominal and/or pelvic external beam radiotherapy History central nervous metastasis History arterial venous thromboembolism within 12 month prior randomization Clinically significant cardiovascular disease within 12 month prior randomization</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primary Peritoneal Cancer</keyword>
</DOC>